Effects of cytokines on antiviral pharmacokinetics: An alternative approach to assessment of drug interactions using bioequivalence guidelines

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 161-165

  Piscitelli, Stephen C ^a,b   Amantea, Michael A ^a,c   Vogel, Susan ^a   Bechtel, Chris ^a   Metcalf, Julia A ^a   Kovacs, Joseph A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CYTOKINE; DIDANOSINE; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030030569     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.161     Document Type: Article

References (25)

1. Chen, Y. L., V. L. Vraux, A. Leneveu, F. Dreyfus, A. Stheneur, I. Florentin, M. De Sousa, J. P. Giroud, B. Flouvat, and L. Chauvelot-Moachon. 1994. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokmetics. Clin. Pharmacol Ther. 55:649-660.
2. Concorde Coordinating Committee. 1994 Concorde: MRC/ANRS randomized double-blind controlled trial of immediate defeired zidovudine in symptom-free HIV infection. Lancet 343:871-881
3. Cordaro, J. A., G. D. Morse, L. Bartos, L. J. Gugino, M. Maliszewski, R. Colomaio, M. Shelton, A. O'Donnell, and R. Hewitt. 1993. Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. Pharmacotherapy 13:369-377.
4. D'Argenio, D. Z., and A. Schumitzky. 1992. Adapt II users guide. Biomedical Simulation Resource, University of Southern California, Los Angeles.
5. Fischl, M., D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, and D. King. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med 317:185-191
6. Food and Drug Administration. 1992. Statistical procedures for bioeqmvalence studies using a standard two-treatment crossover design. Office of Generic Drugs, Division of Bioequivalence. Food and Drug Administration. Rockville, Md
7. Frissen, P. H. J., M. E. van der Ende, C. H. H. T. Napel, H. M. Weigel, G. S. Schreij, R. H. Kauffmann, P. P. Koopmans, A. I. M. Hoepelman, J. B. de Boer, G. J. Weverling, G. Haverkamp, P. Dowd, F. Miedema, R. Schurman, C. A. B. Boucher, and J. M. A. Lange. 1994. Zidovudine and interferon-α combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. J. Infect Dis. 169:1351-1355.
8. Hartshorn, K. L., M. W. Vogt, C. Ting-Chao, R. S. Blumbers, R. Byington, R. T. Schooley, and M. S. Hirsch. 1987. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha interferon. Antimicrob. Agents Chemother. 31:168-172
9. Kassler, W. J., P. Blanc, and R. Greenblatt. 1991 The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch. Intern. Med 15: 2281-2288
10. Knupp, C. A., F. A. Stancato, E. A. Papp, and R. H. Barbhaiya. 1990 Quantitation of didanosine in human plasma and urine by high-performance liquid chiomatography J Chromatogr. 533:282-290
11. + lymphocytes with intermittent courses of continuous interleukin-2 infusions in patients with human immunodeficiency virus infection: a preliminary study. N. Engl. J. Med 332:567-575.
12. Kovacs, J. A., L., Deyton, R. Davey, J. Falloon, K. Zunich, D. Lee, J. A. Metcalf, J. W. Bigley, L. A. Sawyer, K. C. Zoon, H. Masur, A. S. Fauci, and H. C. Lane. 1989. Combined zidovudine and interferon-alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Ann. Intern Med. 111:280-287.
13. Lane, H. C., V. Davey, J. A. Kovacs, J. Feinberg, J. A. Metcalf, B. Herpin, R. Walker, L. Deyton, R. T. Davey, Jr., J. Falloon, M. A. Polis, N. P. Salzman, M. Baseler, H. Masur, and A. S. Fauci. 1990. Interferon-alpha in patients with asymptomatic human immunodeficiency virus infection: a randomized. placebo-controlled trial. Ann. Intern. Med. 112:805-811
14. Morse, G, D., A. Portmore, J. Olson, C. Taylor, C. Plank, and R. C. Reichman. 1990. Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother 34:394-397.
15. Pai, S. M., U. R. Shukla, T. H. Grasela, C. A. Knapp, R. Dolin, F. T. Valentine, C. McLaren, H. A. Lieberman, R. R. Martin, K. A. Pittman, and R. H. Barbhaiya. 1992. Population pharmacokinetic analysis of didanosine. J. Clin. Pharmacol 32:242-247
16. Rook, A. H., H. Masur, H. C. Lane, W. Frederick, T. Kasahara, A. M. Macher, J. Y. Djeu, J. F. Manischewitz, L. Jackson, A. S. Fauci, and G. V. Quinnan, Jr. 1983. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immunodeficiency syndrome J. Clin Invest. 72:398-403.
17. Schuirmann, D. J. 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15:657-680
18. Schwartz, O., and T. C. Merigan. 1990. Interleukin-2 in the treatment of HIV disease. Biotherapy 2:119-136.
19. Sneller, M. C., and H. C. Lane. 1993 Immunologic approaches to the therapy of HIV-1 infection. Ann. N. Y. Acad. Sci. 685:687-696
20. Steimer, J. L., J. Mallet, J. Golmard, and J. Boisieux. 1984 Alternative approaches to estimation of population pharmacokinetic parameters. comparison with the nonlinear mixed effect model. Drug Metab. Rev. 15:265-292.
21. Steinijans, V. W., M. Hartmann, R. Huber, and W. Radtke. 1991. Lack of pharmacokinetic interaction as an equivalence problem Int J. Clin. Pharmacol Toxicol. 29:323-328.
22. Volberding, P. A., S. W. Lagakos, M. A. Koch, C. Pettinelli, M. W. Myers, D. K. Booth, H. H. Balfour, R. C. Reichman, J. A. Bartlett, M. S. Hirsch, R. L. Murphy, W. D. Hardy, K. Soeiro, M. A. Fischl, J. G. Bartlett, T. C. Merigan, N. E. Hyslop, D. D. Richman, F. T. Valentine, and L. Corey. 1990 Zidovudine in asymptomatic human immunodeficiency virus infection. N. Engl J. Med. 322:941-949.
23. Westlake, W. J. 1988. unavailability and bioequivalence of pharmaceutical formulations, p. 329-352 In K F. Peace (ed ), Biopharmaceutical statistics for drug development Marcel Dekker, New York.
24. Whittington, R., and D. Faulds. 1993. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46:446-514.
25. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet Biopharm. 6:165-175.